478 related articles for article (PubMed ID: 7833372)
21. Small cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2.
Yamazaki K; Spruill G; Rhoderick J; Spielman J; Savaraj N; Podack ER
Cancer Res; 1999 Sep; 59(18):4642-50. PubMed ID: 10493519
[TBL] [Abstract][Full Text] [Related]
22. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P
Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853
[TBL] [Abstract][Full Text] [Related]
23. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes: modulation of recognition through retroviral transduction of tumor cells with interleukin 2 complementary DNA and exogenous alpha interferon treatment.
Schendel DJ; Gansbacher B
Cancer Res; 1993 Sep; 53(17):4020-5. PubMed ID: 8358731
[TBL] [Abstract][Full Text] [Related]
24. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
[TBL] [Abstract][Full Text] [Related]
25. Proliferation, phenotype, and cytotoxicity of human lymphocytes isolated from lymph nodes invaded by melanoma cells.
Nakashima M; Janiszewska M; Steplewski Z; Watanabe T; Schuchter L; Koprowski H
Hybridoma; 1994 Jun; 13(3):241-6. PubMed ID: 7927369
[TBL] [Abstract][Full Text] [Related]
26. Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma.
Mukherji B; Guha A; Chakraborty NG; Sivanandham M; Nashed AL; Sporn JR; Ergin MT
J Exp Med; 1989 Jun; 169(6):1961-76. PubMed ID: 2471770
[TBL] [Abstract][Full Text] [Related]
27. Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions.
Gervois N; Guilloux Y; Diez E; Jotereau F
J Exp Med; 1996 May; 183(5):2403-7. PubMed ID: 8642353
[TBL] [Abstract][Full Text] [Related]
28. Immunoselection of a human melanoma resistant to specific lysis by autologous tumor-infiltrating lymphocytes. Possible mechanisms for immunotherapeutic failures.
Topalian SL; Kasid A; Rosenberg SA
J Immunol; 1990 Jun; 144(11):4487-95. PubMed ID: 2160503
[TBL] [Abstract][Full Text] [Related]
29. An autologous T cell clone overcomes intra-melanoma heterogeneity for susceptibility to cell-mediated lysis by using multiple lytic mechanisms: in vitro and in vivo analysis.
Mazzocchi A; Rodolfo M; Parmiani G; Anichini A
Melanoma Res; 1991; 1(3):169-76. PubMed ID: 1841713
[TBL] [Abstract][Full Text] [Related]
30. Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism.
Gamero AM; Ussery D; Reintgen DS; Puleo CA; Djeu JY
Cancer Res; 1995 Nov; 55(21):4988-94. PubMed ID: 7585540
[TBL] [Abstract][Full Text] [Related]
31. Dual recognition of a human cytotoxic T-cell clone for melanoma antigens.
Kubo H; Abe J; Obata F; Nakajima H; Tsunoda M; Ogawa A; Nakayama S; Beck Y; Kohsaka T; Darrow TL; Abdel-Wahab Z; Saida T; Takiguchi M
Cancer Res; 1996 May; 56(10):2368-74. PubMed ID: 8625313
[TBL] [Abstract][Full Text] [Related]
32. MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells. Evidence for restriction by a dominant HLA-A allele.
Crowley NJ; Darrow TL; Quinn-Allen MA; Seigler HF
J Immunol; 1991 Mar; 146(5):1692-9. PubMed ID: 1671580
[TBL] [Abstract][Full Text] [Related]
33. Adhesion molecule-mediated signals regulate major histocompatibility complex-unrestricted and CD3/T cell receptor-triggered cytotoxicity.
Galandrini R; Albi N; Zarcone D; Grossi CE; Velardi A
Eur J Immunol; 1992 Aug; 22(8):2047-53. PubMed ID: 1379184
[TBL] [Abstract][Full Text] [Related]
34. Recognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes: evidence for antigen sharing by tumors derived from the neural crest.
Shamamian P; Mancini M; Kawakami Y; Restifo NP; Rosenberg SA; Topalian SL
Cancer Immunol Immunother; 1994 Aug; 39(2):73-83. PubMed ID: 7519127
[TBL] [Abstract][Full Text] [Related]
35. Recognition of shared melanoma antigen by HLA-A2-restricted cytolytic T cell clones derived from human tumor-infiltrating lymphocytes.
Viret C; Davodeau F; Guilloux Y; Bignon JD; Semana G; Breathnach R; Jotereau F
Eur J Immunol; 1993 Jan; 23(1):141-6. PubMed ID: 8419164
[TBL] [Abstract][Full Text] [Related]
36. Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with gamma-interferon genes.
Ogasawara M; Rosenberg SA
Cancer Res; 1993 Aug; 53(15):3561-8. PubMed ID: 8101762
[TBL] [Abstract][Full Text] [Related]
37. Generation of human autologous melanoma-specific cytotoxic T cells from tumor-involved lymph nodes.
Maeda K; Lafreniere R; McKinnon JG; Jerry LM
Mol Biother; 1991 Jun; 3(2):95-102. PubMed ID: 1910625
[TBL] [Abstract][Full Text] [Related]
38. Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression.
Matsuda M; Salazar F; Petersson M; Masucci G; Hansson J; Pisa P; Zhang QJ; Masucci MG; Kiessling R
J Exp Med; 1994 Dec; 180(6):2371-6. PubMed ID: 7964510
[TBL] [Abstract][Full Text] [Related]
39. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
Rivoltini L; Kawakami Y; Sakaguchi K; Southwood S; Sette A; Robbins PF; Marincola FM; Salgaller ML; Yannelli JR; Appella E
J Immunol; 1995 Mar; 154(5):2257-65. PubMed ID: 7868898
[TBL] [Abstract][Full Text] [Related]
40. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2.
Correale P; Micheli L; Vecchio MT; Sabatino M; Petrioli R; Pozzessere D; Marsili S; Giorgi G; Lozzi L; Neri P; Francini G
Br J Cancer; 2001 Nov; 85(11):1722-30. PubMed ID: 11742494
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
